[HTML][HTML] Improved survival and quality of life through an integrative, multidisciplinary oncological approach: pathophysiological analysis of four clinical cancer cases …
M Berretta, A Morra, R Taibi, F Monari… - Frontiers in …, 2022 - frontiersin.org
Objectives: According to the National Cancer Institute, the integrative medicine (IM)
approach to medical care combines standard medicine with complementary and alternative …
approach to medical care combines standard medicine with complementary and alternative …
Pemetrexed in advanced non-small-cell lung cancer
AD Fuld, KH Dragnev, JR Rigas - Expert Opinion on …, 2010 - Taylor & Francis
Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …
[HTML][HTML] A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung …
JD Hainsworth, CL Cebotaru, V Kanarev… - Journal of Thoracic …, 2010 - Elsevier
Introduction: AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed
to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second-or third-line …
to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second-or third-line …
Activity of pemetrexed on brain metastases from non-small cell lung cancer
A Bearz, I Garassino, M Tiseo, O Caffo, H Soto-Parra… - Lung Cancer, 2010 - Elsevier
Brain metastases from Non-Small Cell Lung Cancer are usually associated with poor
prognosis and up to now chemotherapy has shown a modest activity upon cerebral …
prognosis and up to now chemotherapy has shown a modest activity upon cerebral …
[HTML][HTML] Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non–small-cell lung Cancer treated with Pemetrexed
DC Christoph, BR Asuncion, B Hassan, C Tran… - Journal of thoracic …, 2013 - Elsevier
Introduction: Folate receptor alpha (FRA) regulates cellular uptake of folates and antifolates.
Information about FRA protein expression in metastatic non–small-cell lung cancer (NSCLC) …
Information about FRA protein expression in metastatic non–small-cell lung cancer (NSCLC) …
The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung …
MH Chang, JS Ahn, J Lee, KH Kim, YH Park, J Han… - Lung Cancer, 2010 - Elsevier
BACKGROUND: Pemetrexed is one of the standard second-line therapies in advanced non-
small cell lung cancer (NSCLC). Currently, there are no standard cytotoxic treatments …
small cell lung cancer (NSCLC). Currently, there are no standard cytotoxic treatments …
[PDF][PDF] Clinical presentation and outcome of non-AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors …
M Berretta, F Martellotta, R Di Francia… - Eur Rev Med …, 2015 - europeanreview.org
The advent of antiretroviral ther-apy (ART) has markedly extended the survival rates of
patients with human immunodeficiency virus (HIV), leading to suppression even though not …
patients with human immunodeficiency virus (HIV), leading to suppression even though not …
Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo
Q Tan, J Li, H Yin, L Wang, W Tang, F Zhao… - Investigational new …, 2010 - Springer
Summary Ethaselen (1, 2-[bis (1, 2-Benzisoselenazolone-3 (2H)-ketone)] ethane, BBSKE),
as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been …
as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been …
Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer
JM Sun, KW Lee, JH Kim, YJ Kim… - Japanese Journal of …, 2009 - academic.oup.com
Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …
Pemetrexed for the treatment of non-small cell lung cancer
C Genova, E Rijavec, A Truini, S Coco… - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death
worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have …
worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have …